Cellular agriculture

Cellular agriculture is the production of agricultural products — meat, milk, eggs, leather, silk — directly from cells rather than from whole animals. It collapses the animal out of the supply chain while keeping the molecules that animal-derived products are made of. Two distinct technology families sit under the umbrella, each with its own biology, economics, and regulatory path.

Definition and scope

Cultivated meat (also “cultured” or “cell-based” meat) grows animal muscle and fat tissue from stem or progenitor cells in bioreactors. The cells are real animal cells; the tissue is real animal tissue. Only the slaughter is missing.

Precision fermentation uses engineered microbes — yeasts, fungi, or bacteria — as cell factories to secrete specific animal proteins: whey, casein, ovalbumin, collagen, lactoferrin, heme. The protein is molecularly identical to the animal-derived version; the microbe is simply the production host. The same platform has produced recombinant human insulin since 1982 and chymosin (the rennet used in most hard cheeses) since 1990. Dairy and egg proteins are recent extensions of a mature industrial biology.

Recombinant and biomass fermentation sit nearby. Biomass fermentation grows the microbe itself as the food (as with mycoprotein); recombinant systems produce bioactive molecules — growth factors, heme, enzymes — that feed into either cultivated meat or plant-based formulations. Rubio et al. (2020) in Nature Food lay out how these streams relate and where they diverge from conventional plant-based meat.

History

Winston Churchill anticipated the idea in a 1931 essay — “we shall escape the absurdity of growing a whole chicken in order to eat the breast or wing, by growing these parts separately under a suitable medium.” The technical groundwork arrived seventy years later: NASA- funded experiments grew goldfish muscle explants in 2002, and Jason Matheny founded New Harvest in 2004 as the first nonprofit dedicated to cultured meat research.

The defining public moment came on 5 August 2013, when Mark Post, a vascular physiologist at Maastricht University, served a cultivated beef burger at a London press event. The patty, assembled from roughly 20,000 thin strands of bovine muscle grown over three months, cost approximately 250,000 euros, underwritten by Google co-founder Sergey Brin. Post had outlined the technical path the year before (Post, 2012), framing stem-cell-based meat as plausible engineering rather than speculation.

What followed was a company formation wave. Memphis Meats (now UPSIDE Foods) launched in 2015; Mosa Meat, Post’s own spinout, in 2016; Aleph Farms in 2017; GOOD Meat (a division of Eat Just) pivoted into cultivated chicken around the same time. On the fermentation side, Perfect Day (recombinant whey) was founded in 2014, Clara Foods — later The EVERY Company — for recombinant egg proteins in 2014, and Formo in Germany for recombinant dairy in 2019. Good Food Institute (2023) counts roughly 170 cultivated-meat companies and 160 fermentation companies worldwide.

Technical fundamentals

Four components determine whether cultivated meat works technically and economically.

Cell lines. Producers need cells that proliferate for many doublings without senescing and then differentiate into muscle, fat, or connective tissue on cue. Options include primary satellite cells (finite lifespan), embryonic or induced pluripotent stem cells (harder to control), and spontaneously or engineered immortalised lines. Food-grade, non-GMO, non-tumorigenic immortal lines for major livestock species remain an active research frontier.

Growth media. Cells are bathed in a liquid containing amino acids, glucose, salts, vitamins, and — critically — growth factors and signalling proteins. Historically this meant fetal bovine serum (FBS), which is expensive, variable, and animal-derived. The field has shifted to serum-free formulations relying on recombinant growth factors (FGF, IGF, insulin, transferrin, albumin) produced by precision fermentation. Humbird (2021) identified medium cost as the dominant driver of cultivated-meat economics.

Scaffolds. Muscle cells need three-dimensional structure to form fibres and to allow nutrient and oxygen exchange through the tissue. Edible scaffolds under investigation include textured soy, decellularised plant tissues, alginate, collagen, and electrospun polysaccharide microfibres. Unstructured formats — nuggets, sausages, patties — tolerate less scaffolding than a whole steak.

Bioreactors. Cells grow in stirred-tank, perfusion, or hollow- fibre reactors at volumes extrapolated from pharmaceutical bioprocessing. Scaling to meat-commodity volumes would require tens of thousands of bioreactor-litres per facility, with sterility, oxygen transfer, and shear stress as binding constraints.

Economic and life-cycle state of the science

The economic and environmental case for cultivated meat is genuinely contested.

Tuomisto & Teixeira de Mattos (2011), the first peer-reviewed LCA of cultured meat, modelled a cyanobacteria-hydrolysate-based medium and projected 78–96 percent lower greenhouse-gas emissions, 99 percent lower land use, and 82–96 percent lower water use than conventional European meat production. The headline numbers travelled widely but depended on assumptions — chiefly a cheap, photosynthetic feedstock — that no current production system uses.

Humbird (2021), in Biotechnology and Bioengineering, applied rigorous pharmaceutical-scale bioprocess engineering and concluded that under realistic assumptions cultivated meat would struggle to fall below roughly 37 dollars per kilogram, with medium cost and bioreactor capital as the dominant constraints. The paper became the industry’s bear-case anchor.

Sinke & Swartz (2021), a CE Delft techno-economic and life-cycle analysis commissioned by the Good Food Institute, projected that by 2030 cultivated meat produced at scale with renewable-powered facilities could reach 5.66 dollars per kilogram and cut climate impact by up to 92 percent versus beef. The GFI report uses more optimistic assumptions than Humbird on medium cost and cell-line performance, and the gap between the two papers maps roughly onto the gap between industry projections and independent engineering critique.

Good Food Institute’s annual State of the Industry reports track the actual data as it emerges — investment flows, facility build-outs, published production costs, and regulatory filings. The honest summary as of 2024: several companies have demonstrated kilogram- scale production and small commercial sales, but none has publicly demonstrated the cost trajectory required for commodity-scale competition with conventional meat.

Regulatory milestones

Singapore became the first jurisdiction to authorise cultivated meat for sale when the Singapore Food Agency approved Eat Just’s GOOD Meat cultivated chicken in December 2020. The product debuted at the 1880 restaurant at modest volumes.

The United States followed in 2022–2023. The FDA issued “no questions” letters confirming the safety of cultured cell material for UPSIDE Foods in November 2022 and GOOD Meat in March 2023. USDA’s Food Safety and Inspection Service issued grants of inspection and approved product labels for both companies in June 2023, clearing the full regulatory path. Cultivated chicken went on sale at Bar Crenn in San Francisco and China Chilcano in Washington DC shortly afterwards, at chef-tasting volumes.

Israel approved Aleph Farms’ cultivated beef in January 2024. The European Union operates under its Novel Foods Regulation, under which no cultivated-meat application has yet been approved; several are in review. Italy passed a pre-emptive ban in 2023. Florida and Alabama enacted state-level sales bans in 2024.

Key companies

On the cultivated-meat side, the companies that have driven the field include UPSIDE Foods (California, the 2015 Memphis Meats rename), GOOD Meat (division of Eat Just, first to reach commercial sale), Mosa Meat (Maastricht, Mark Post’s spinout, cultivated beef), Aleph Farms (Israel, whole-cut steak and Israeli regulatory approval), BlueNalu (California, cultivated seafood), and Wildtype (California, cultivated salmon).

On the precision-fermentation side: Perfect Day (recombinant whey, now in commercial ice cream and protein powder), The EVERY Company (recombinant egg proteins including ovomucoid and ovalbumin used by Pressed and others), and Formo (recombinant dairy proteins, with ricotta-style products launching in 2024). Triton Algae Innovations, Motif FoodWorks, and Impossible Foods (for its soy leghemoglobin) also operate recombinant-protein platforms.

Where this sits in the vegan argument

Cellular agriculture does not make animals unnecessary to an ethical vegan — an animal cell in a bioreactor is still an animal cell, and many vegans will decline cultivated meat on that ground. It does, however, address the two questions plant-based substitutes have the hardest time answering: can non-plant-curious consumers get the molecules they want without animal slaughter, and can the environmental footprint of protein fall without persuading everyone to switch categories. If the technology delivers on the Sinke & Swartz scenarios rather than the Humbird ones, it becomes one of the largest single levers in food-system decarbonisation. If it stalls at the Humbird ceiling, precision fermentation remains the commercial backbone and cultivated meat remains a narrow luxury product. The science pillar has no stake in which outcome materialises — only in reading the evidence honestly as it comes in.